Mitsubishi UFJ Trust & Banking Corp cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 70,648 shares of the biopharmaceutical company's stock after selling 5,676 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned 0.06% of Regeneron Pharmaceuticals worth $50,325,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $26,000. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $28,000. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares during the period. Avalon Trust Co bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Finally, Crowley Wealth Management Inc. acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $36,000. 83.31% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on the stock. TD Cowen dropped their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a research report on Tuesday, February 4th. Robert W. Baird cut their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 5th. BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research report on Tuesday, February 4th. Truist Financial cut their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. Finally, Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 17th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $973.13.
Check Out Our Latest Stock Analysis on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Stock Up 0.2 %
REGN traded up $1.53 during mid-day trading on Friday, reaching $637.36. 805,912 shares of the stock were exchanged, compared to its average volume of 673,409. Regeneron Pharmaceuticals, Inc. has a 1 year low of $629.02 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a market capitalization of $69.68 billion, a PE ratio of 16.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a 50 day moving average price of $683.88 and a two-hundred day moving average price of $797.99.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the business posted $11.86 EPS. The company's revenue for the quarter was up 10.3% on a year-over-year basis. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.55%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.
Regeneron Pharmaceuticals Profile
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Recommended Stories
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
